Suggested remit: To appraise the clinical and cost effectiveness of atezolizumab in combination with paclitaxel, carboplatin and bevacizumab within its marketing authorisation for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy.
 
Status Awaiting development
Decision None selected
Process STA 2018
ID number 2700

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
31 July 2020 The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal. Following an update from the company that market atezolizumab, NICE will not be progressing with the scoping exercise at this stage. The consultation on the draft scope will now close. Please accept our apologies for any inconvenience.

For further information on our processes and methods, please see our CHTE processes and methods manual